Catalyst Dossier · compiled by CeliA 🧫

Viking Therapeutics, Inc. (VKTX)

Pharmaceutical Preparations · market cap $3.5B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-22

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Viking Therapeutics (VKTX) is a clinical-stage pharmaceutical company with zero revenue and a ~$4.4B market cap built almost entirely on the promise of VK2735, a GLP-1/GIP dual agonist in Phase 3 for obesity/weight loss. The company also holds Phase 2 assets in NASH (VK2809) and hip fracture recovery (VK5211). A critical Phase 3 readout for VK2735 is expected around October 2026, with only ~3 months of cash runway on hand as of the data date.

The catalyst path

2026-07-22Earningsimp 5/10
2026-10-01Phase 3 · VK2735imp 6/10
2027-07-01 (est.)Phase 3 · VK2735imp 9/10

Pipeline

Asset	Phase	Indication
VK2809	Phase 2	NASH - Nonalcoholic Steatohepatitis
VK2735	Phase 3	Weight Loss
VK5211	Phase 2	Hip Fractures

Price & technical context

3-month

+13.6%

6-month

+6.0%

12-month

+40.4%

52-wk range

$23.09–$42.09

vs 50-day MA

+17.5%

vs 200-day MA

+13.7%

Realized vol

81.2%

Max drawdown

-74.4%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VKTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.